Brief: Lexicon Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Pilavapadin In The Treatment Of Diabetic Peripheral Neuropathic Pain
21/01/2026 13:31
Jan 21 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O: LEXICON PHARMACEUTICALS ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA FOR PILAVAPADIN IN THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN LEXICON PHARMACEUTICALS INC - FDA RAISED NO OBJECTIONS TO ADVANCEMENT OF PILAVAPADIN INTO PHASE 3 DEVELOPMENT Source text: ID:nGNX6204GG Further company coverage: LXRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview